A 31 year old female with hypertension and proteinuria secondary to IgA nephropathy, currently treated with an ARB, presents to clinic stating that she would like to become pregnant.
What is the risk of fetal morbidity in the setting of …
Category: Renal
Clinical Correlations
FDA Black Box Warning on Gadolinium
May 24, 2007Back in December we reported on the FDA cautioning practioners about the use of gadolinium (an mri contrast agent) in patients with chronic kidney disease. The FDA is now requesting a black box warning stating “that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, …
First Direct Renin Inhibitor Approved for Hypertension
March 29, 2007
Commentary By: Josh Olstein, PGY-3
Earlier this month the FDA approved Tekturna (aliskiren) the first drug in a novel class of antihypertensives that work by directly inhibiting renin. While Novartis has yet to release pricing information, don’t expect to see this new …
Breaking News: FDA Advises Caution with Gadolinium Based Contrast
December 27, 2006
Commentary By: Minisha Sood PGY-3
The FDA has received reports of 90 patients with moderate to end-stage kidney disease who have undergone MRI or MRA with a gadolinium-based contrast agent and subsequently developed a new disease known as Nephrogenic …
Epogen and Anemia-Less is More (Part 2)
December 14, 2006Commentary By David Goldfarb, M.D. Professor of Medicine, NYU Medical Center, Chief Nephrology Section VA New York Harbor
2 weeks ago we reported on 2 lead articles in …
Epogen and Anemia-Less is More
November 17, 2006
Singh AK et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 Nov 16; 355:2085-98.
Drüeke TB et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. …